Eterna Therapeutics Net Worth
Eterna Therapeutics Net Worth Breakdown | ERNA |
Eterna Therapeutics Net Worth Analysis
Eterna Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eterna Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eterna Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eterna Therapeutics' net worth analysis. One common approach is to calculate Eterna Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eterna Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eterna Therapeutics' net worth. This approach calculates the present value of Eterna Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eterna Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eterna Therapeutics' net worth. This involves comparing Eterna Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eterna Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Eterna Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eterna Therapeutics' net worth research are outlined below:
| Eterna Therapeutics is way too risky over 90 days horizon | |
| Eterna Therapeutics appears to be risky and price may revert if volatility continues | |
| Eterna Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Eterna Therapeutics Stock Price Down 5.4 percent - Defense World |
Eterna Therapeutics Quarterly Good Will |
|
Eterna Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eterna Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eterna Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Eterna Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eterna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eterna Therapeutics backward and forwards among themselves. Eterna Therapeutics' institutional investor refers to the entity that pools money to purchase Eterna Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | A. Montag & Associates Inc | 2023-12-31 | 70.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 50.0 | Royal Bank Of Canada | 2023-12-31 | 31.0 | Wells Fargo & Co | 2023-12-31 | 28.0 | Group One Trading, Lp | 2023-12-31 | 19.0 | Citigroup Inc | 2024-03-31 | 15.0 | Jpmorgan Chase & Co | 2023-12-31 | 14.0 | Aspire Private Capital, Llc | 2024-03-31 | 10.0 | Nbc Securities Inc | 2024-03-31 | 10.0 | Lake Street Advisors Group, Llc | 2023-12-31 | 521 K | Cypress Point Wealth Management, Llc | 2023-12-31 | 94.4 K |
Follow Eterna Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.77 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eterna Therapeutics's market, we take the total number of its shares issued and multiply it by Eterna Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Eterna Therapeutics' profitablity
Eterna Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Eterna Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Eterna Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Eterna Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Eterna Therapeutics' profitability requires more research than a typical breakdown of Eterna Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (9.70) | (10.19) |
When accessing Eterna Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eterna Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eterna Therapeutics' profitability and make more informed investment decisions.
The data published in Eterna Therapeutics' official financial statements usually reflect Eterna Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eterna Therapeutics. For example, before you start analyzing numbers published by Eterna accountants, it's critical to develop an understanding of what Eterna Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Eterna Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eterna Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eterna Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eterna Therapeutics. Please utilize our Beneish M Score to check the likelihood of Eterna Therapeutics' management manipulating its earnings.
Evaluate Eterna Therapeutics' management efficiency
Eterna Therapeutics has return on total asset (ROA) of (0.3619) % which means that it has lost $0.3619 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.022) %, meaning that it created substantial loss on money invested by shareholders. Eterna Therapeutics' management efficiency ratios could be used to measure how well Eterna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 25, 2024, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.51. At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 114 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.42 | 0.40 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 0.04 | 0.03 | |
| Enterprise Value Over EBITDA | (2.24) | (2.13) | |
| Price Book Value Ratio | 4.28 | 6.28 | |
| Enterprise Value Multiple | (2.24) | (2.13) | |
| Price Fair Value | 4.28 | 6.28 | |
| Enterprise Value | 149.7 M | 82.8 M |
The analysis of Eterna Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Eterna Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Eterna Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 682.1785 | Revenue 68 K | Revenue Per Share 0.013 | Return On Equity (3.02) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eterna Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eterna Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eterna Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sidhu Roger over three weeks ago Acquisition by Sidhu Roger of 161300 shares of Eterna Therapeutics at 9.96 subject to Rule 16b-3 | ||
Bristol James Arthur over three weeks ago Acquisition by Bristol James Arthur of 124525 shares of Eterna Therapeutics at 1.74 subject to Rule 16b-3 | ||
Sandra Gurrola over a month ago Acquisition by Sandra Gurrola of 114500 shares of Eterna Therapeutics at 1.93 subject to Rule 16b-3 |
Eterna Therapeutics Corporate Filings
10Q | 14th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 29th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 22nd of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 18th of March 2024 An amendment to a previously filed Form 10-K | ViewVerify |
Eterna Therapeutics Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eterna Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Eterna Therapeutics Corporate Management
Elected by the shareholders, the Eterna Therapeutics' board of directors comprises two types of representatives: Eterna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eterna. The board's role is to monitor Eterna Therapeutics' management team and ensure that shareholders' interests are well served. Eterna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eterna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jackson | Chief Officer | Profile | |
| Susan McClatchey | VP Quality | Profile | |
| Sandra Gurrola | Principal Finance | Profile | |
| Megan Yung | Chief Officer | Profile | |
| Roger MD | Chief Officer | Profile | |
| Matthew Angel | CEO Director | Profile |
How to buy Eterna Stock?
The net worth of Eterna Therapeutics is the difference between its total assets and liabilities. Eterna Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Eterna Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Eterna Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Eterna Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Eterna Therapeutics stock.Already Invested in Eterna Therapeutics?
The danger of trading Eterna Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eterna Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eterna Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eterna Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets |
Is Eterna Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.08) | Revenue Per Share 0.013 | Return On Assets (0.36) | Return On Equity (3.02) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.